AR084309A1 - Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina - Google Patents
Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diaminaInfo
- Publication number
- AR084309A1 AR084309A1 ARP110104703A ARP110104703A AR084309A1 AR 084309 A1 AR084309 A1 AR 084309A1 AR P110104703 A ARP110104703 A AR P110104703A AR P110104703 A ARP110104703 A AR P110104703A AR 084309 A1 AR084309 A1 AR 084309A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenyl
- piperidin
- methyl
- diamine
- propan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061424194P | 2010-12-17 | 2010-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR084309A1 true AR084309A1 (es) | 2013-05-08 |
Family
ID=45464892
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110104703A AR084309A1 (es) | 2010-12-17 | 2011-12-15 | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina |
ARP210100698A AR122395A2 (es) | 2010-12-17 | 2021-03-19 | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100698A AR122395A2 (es) | 2010-12-17 | 2021-03-19 | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina |
Country Status (35)
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3121171T1 (sl) * | 2010-12-17 | 2018-11-30 | Novartis Ag | Kristalinične oblike 5-kloro-N2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-N4-(2- (propan-2-sulfonil)-fenil)-pirimidin-2,4-diamina |
RU2675850C2 (ru) | 2012-11-06 | 2018-12-25 | Шанхай Фокон Фармасьютикал Ко Лтд | Ингибиторы alk-киназы |
KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
CN105272921A (zh) * | 2014-06-09 | 2016-01-27 | 江苏奥赛康药业股份有限公司 | 一种制备Ceritinib的方法及其中间体化合物 |
CN105294649B (zh) * | 2014-07-30 | 2019-05-14 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
CN105294650A (zh) * | 2014-08-01 | 2016-02-03 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
SG11201702980QA (en) | 2014-10-21 | 2017-05-30 | Ariad Pharma Inc | Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine |
WO2016081538A1 (en) | 2014-11-18 | 2016-05-26 | Teva Pharmaceuticals International Gmbh | Solid state forms of ceritinib and salts thereof |
CN105601614A (zh) * | 2014-11-21 | 2016-05-25 | 奥浦顿(上海)医药科技有限公司 | 一种色瑞替尼晶型及其制备方法 |
WO2016082795A1 (zh) * | 2014-11-28 | 2016-06-02 | 苏州晶云药物科技有限公司 | 色瑞替尼的晶型i及其制备方法 |
CN105622577A (zh) * | 2014-11-29 | 2016-06-01 | 江苏先声药业有限公司 | 一种色瑞替尼的新晶型及其制备方法 |
WO2016108123A2 (en) * | 2014-12-17 | 2016-07-07 | Dr. Reddy’S Laboratories Limited | Pure amorphous and amorphous solid dispersion of ceritinib |
WO2016098070A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
WO2016098042A1 (en) * | 2014-12-19 | 2016-06-23 | Novartis Ag | Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders |
EP3328848A1 (en) | 2015-07-28 | 2018-06-06 | Zentiva, K.S. | Solid forms of ceritinib free base |
CN105061397B (zh) * | 2015-08-07 | 2018-01-02 | 武汉英普瑞医药科技有限公司 | 一种色瑞替尼的c型晶型及其制备方法与应用 |
CN106699743B (zh) | 2015-11-05 | 2020-06-12 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类衍生物及其用途 |
WO2017152858A1 (zh) * | 2016-03-11 | 2017-09-14 | 苏州晶云药物科技有限公司 | 色瑞替尼的晶型及其制备方法 |
WO2017158619A1 (en) | 2016-03-15 | 2017-09-21 | Natco Pharma Limited | A modified process for the preparation of ceritinib and amorphous form of ceritinib |
JP2019196359A (ja) * | 2019-06-17 | 2019-11-14 | ノバルティス アーゲー | ピリミジン誘導体およびそれらの中間体を調製する化学的方法 |
GB201915618D0 (en) | 2019-10-28 | 2019-12-11 | Univ Oslo | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
EP4092021A4 (en) * | 2020-01-17 | 2023-01-25 | Shandong Xuanzhu Pharma Co., Ltd. | CRYSTALLINE FORM OF A POLYCYCLIC ANAPLASIC LYMPHOMA KINASE INHIBITOR |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
EP1660458B1 (en) * | 2003-08-15 | 2012-01-25 | Novartis AG | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
EP2537830A1 (en) * | 2006-12-08 | 2012-12-26 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
ME00811B (me) * | 2006-12-08 | 2012-03-20 | Novartis Ag | JEDINJENJA l KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZE |
KR101174201B1 (ko) * | 2007-08-28 | 2012-08-16 | 아이알엠 엘엘씨 | 키나제 억제제로서의 2-비페닐아미노-4-아미노피리미딘 유도체 |
AU2008296479A1 (en) * | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
CN102131788B (zh) * | 2008-04-07 | 2014-03-19 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
NO2300013T3 (US07585860-20090908-C00112.png) * | 2008-05-21 | 2018-02-03 | ||
CA2763717A1 (en) * | 2009-06-10 | 2010-12-16 | Cellzome Limited | Pyrimidine derivatives as zap-70 inhibitors |
TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑的2-芳基咪唑衍生物 |
SI3121171T1 (sl) * | 2010-12-17 | 2018-11-30 | Novartis Ag | Kristalinične oblike 5-kloro-N2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-N4-(2- (propan-2-sulfonil)-fenil)-pirimidin-2,4-diamina |
PT2651902T (pt) | 2010-12-17 | 2018-02-01 | Reata Pharmaceuticals Inc | Enonas tricíclicas de pirazolilo e pirimidinilo como moduladores de inflamação antioxidantes |
BR112013015166A2 (pt) | 2010-12-17 | 2016-07-12 | Du Pont | composto selecionado a partir de fórmula 1, composição fungicida e método para controlar doenças de plantas |
CN105294650A (zh) | 2014-08-01 | 2016-02-03 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
WO2016081538A1 (en) | 2014-11-18 | 2016-05-26 | Teva Pharmaceuticals International Gmbh | Solid state forms of ceritinib and salts thereof |
US9566882B2 (en) | 2014-11-21 | 2017-02-14 | Tk Holdings Inc. | Airbag module |
CN105622577A (zh) | 2014-11-29 | 2016-06-01 | 江苏先声药业有限公司 | 一种色瑞替尼的新晶型及其制备方法 |
SG11201704343SA (en) | 2014-12-04 | 2017-06-29 | Bristol Myers Squibb Co | Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma) |
WO2016098070A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
EP3328848A1 (en) | 2015-07-28 | 2018-06-06 | Zentiva, K.S. | Solid forms of ceritinib free base |
CN105061397B (zh) | 2015-08-07 | 2018-01-02 | 武汉英普瑞医药科技有限公司 | 一种色瑞替尼的c型晶型及其制备方法与应用 |
-
2011
- 2011-12-15 SI SI201131583T patent/SI3121171T1/sl unknown
- 2011-12-15 DK DK11806079.7T patent/DK2651918T3/en active
- 2011-12-15 PT PT118060797T patent/PT2651918T/pt unknown
- 2011-12-15 HU HUE16167355A patent/HUE041845T2/hu unknown
- 2011-12-15 RU RU2013132947A patent/RU2599785C3/ru active Protection Beyond IP Right Term
- 2011-12-15 KR KR1020137018605A patent/KR20130130022A/ko not_active Application Discontinuation
- 2011-12-15 CN CN201710063792.0A patent/CN106831716A/zh active Pending
- 2011-12-15 JP JP2013544762A patent/JP5916752B2/ja active Active
- 2011-12-15 EP EP16167355.3A patent/EP3121171B1/en active Active
- 2011-12-15 CA CA2821102A patent/CA2821102C/en active Active
- 2011-12-15 RS RS20181240A patent/RS57771B1/sr unknown
- 2011-12-15 CN CN202210792464.5A patent/CN114989139A/zh active Pending
- 2011-12-15 NZ NZ610713A patent/NZ610713A/en not_active IP Right Cessation
- 2011-12-15 CN CN201410457562.9A patent/CN104262324A/zh active Pending
- 2011-12-15 SG SG2013039342A patent/SG190856A1/en unknown
- 2011-12-15 EP EP18186197.2A patent/EP3453708B8/en active Active
- 2011-12-15 PE PE2013001425A patent/PE20140698A1/es not_active Application Discontinuation
- 2011-12-15 WO PCT/US2011/065030 patent/WO2012082972A1/en active Application Filing
- 2011-12-15 ES ES11806079.7T patent/ES2643016T3/es active Active
- 2011-12-15 EP EP11806079.7A patent/EP2651918B1/en not_active Revoked
- 2011-12-15 MY MYPI2013001848A patent/MY164810A/en unknown
- 2011-12-15 RU RU2016136823A patent/RU2746159C2/ru active
- 2011-12-15 CN CN202011050061.0A patent/CN112125884A/zh active Pending
- 2011-12-15 ES ES16167355T patent/ES2696526T3/es active Active
- 2011-12-15 MY MYPI2016001551A patent/MY177742A/en unknown
- 2011-12-15 MX MX2013006952A patent/MX338210B/es active IP Right Grant
- 2011-12-15 KR KR1020197005138A patent/KR20190022903A/ko active Search and Examination
- 2011-12-15 SI SI201131289T patent/SI2651918T1/sl unknown
- 2011-12-15 DK DK16167355.3T patent/DK3121171T3/en active
- 2011-12-15 PT PT16167355T patent/PT3121171T/pt unknown
- 2011-12-15 CN CN201610217386.0A patent/CN106008462A/zh active Pending
- 2011-12-15 LT LTEP11806079.7T patent/LT2651918T/lt unknown
- 2011-12-15 AU AU2011343775A patent/AU2011343775B2/en active Active
- 2011-12-15 AR ARP110104703A patent/AR084309A1/es not_active Application Discontinuation
- 2011-12-15 SG SG10201510082XA patent/SG10201510082XA/en unknown
- 2011-12-15 BR BR112013015000A patent/BR112013015000A2/pt not_active Application Discontinuation
- 2011-12-15 KR KR1020187007996A patent/KR20180032680A/ko not_active Application Discontinuation
- 2011-12-15 CN CN201710063793.5A patent/CN107056751A/zh active Pending
- 2011-12-15 US US13/993,217 patent/US9309229B2/en active Active
- 2011-12-15 KR KR1020207009828A patent/KR102325775B1/ko active IP Right Grant
- 2011-12-15 PL PL16167355T patent/PL3121171T3/pl unknown
- 2011-12-15 PL PL11806079T patent/PL2651918T3/pl unknown
- 2011-12-15 LT LTEP16167355.3T patent/LT3121171T/lt unknown
- 2011-12-15 CN CN201180060435XA patent/CN103282359A/zh active Pending
- 2011-12-15 ES ES18186197T patent/ES2905973T3/es active Active
- 2011-12-16 TW TW105112710A patent/TWI576344B/zh active
- 2011-12-16 TW TW100146987A patent/TWI576343B/zh active
-
2013
- 2013-05-17 TN TNP2013000216A patent/TN2013000216A1/fr unknown
- 2013-05-17 ZA ZA2013/03599A patent/ZA201303599B/en unknown
- 2013-05-20 IL IL226474A patent/IL226474A/en active IP Right Grant
- 2013-06-14 CL CL2013001723A patent/CL2013001723A1/es unknown
- 2013-06-17 GT GT201300153A patent/GT201300153A/es unknown
- 2013-06-28 MA MA36066A patent/MA34771B1/fr unknown
- 2013-07-04 CO CO13158446A patent/CO6801792A2/es not_active Application Discontinuation
- 2013-07-16 EC ECSP13012770 patent/ECSP13012770A/es unknown
-
2016
- 2016-03-02 US US15/058,489 patent/US20160175305A1/en not_active Abandoned
-
2017
- 2017-10-03 HR HRP20171477TT patent/HRP20171477T1/hr unknown
- 2017-10-11 CY CY20171101064T patent/CY1119474T1/el unknown
-
2018
- 2018-10-22 HR HRP20181737TT patent/HRP20181737T1/hr unknown
- 2018-11-09 CY CY181101192T patent/CY1121017T1/el unknown
-
2021
- 2021-03-19 AR ARP210100698A patent/AR122395A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR122395A2 (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina | |
CL2019001714A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer. | |
BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
AR084824A1 (es) | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas | |
CL2008001868A1 (es) | Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica | |
BR112014016287A2 (pt) | composto, composição farmacêutica, método para aumentar a inclusão de exon 7 de smn2, método para aumentar a quantidade de proteína, método para o tratamento de sma | |
CY1112429T1 (el) | Υποκατεστημενα παραγωγα σουλφοναμιδιου | |
EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
ECSP13012611A (es) | Derivados de pirazol-aminopirimidina como moduladores de la lrrk2 | |
UY31419A1 (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen | |
EA201690520A1 (ru) | Способ получения замещенных 5-фтор-1h-пиразолопиридинов | |
GEP20196949B (en) | 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors | |
EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
EA201100921A1 (ru) | Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ | |
BRPI1009783A2 (pt) | compostos para o tratamento de distúrbios metabólicos. | |
BRPI1013245A2 (pt) | "composto para o tratamento de distúrbios metabólicos" | |
EA201590653A1 (ru) | Терапевтическое средство при дислипидемии | |
CU20170158A7 (es) | Derivados sustituidos de 1-arilnaftiridina-3-carboxamidas y su utilidad en el tratamiento o prevención de enfermedades cardiovasculares y renales | |
EA201590562A1 (ru) | Бензамиды | |
BRPI1009781A2 (pt) | compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos | |
EA201590735A1 (ru) | 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств | |
EA201200616A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
GEP20156319B (en) | Asymmetric ureas and medical uses thereof | |
AR087672A1 (es) | Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |